Prothena Corporation plc (NASDAQ: PRTA) announced the publication of Phase 2 clinical trial data for coramitug, formerly known as PRX004 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE